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Effect Size Estimates of Lifestyle and Dietary Changes on
All-Cause Mortality in Coronary Artery Disease Patients
A Systematic Review
J.A. Iestra, RD; D. Kromhout, MPH, PhD; Y.T. van der Schouw, PhD; D.E. Grobbee, MD, PhD;
H.C. Boshuizen, PhD; W.A. van Staveren, PhD
Background—Guidelines for lifestyle and dietary modification in patients with coronary artery disease (CAD) are mainly
supported by evidence from general population studies. CAD patients, however, differ from the general population in
age (older) and treatment with preventive drugs. This review seeks to provide evidence for a prognostic benefit of
lifestyle and dietary recommendations from studies in CAD patients.
Methods and Results—A literature search was performed on the effect of lifestyle and dietary changes on mortality in
CAD patients. Prospective cohort studies and randomized controlled trials of patients with established CAD were
included if they reported all-causes mortality and had at least 6 months of follow-up. The effect estimates of smoking
cessation (relative risk [RR], 0.64; 95% CI, 0.58 to 0.71), increased physical activity (RR, 0.76; 95% CI, 0.59 to 0.98),
and moderate alcohol use (RR, 0.80; 95% CI, 0.78 to 0.83) were studied most extensively. For the 6 dietary goals, data
were too limited to provide reliable effect size estimates. Combinations of dietary changes were associated with reduced
mortality (RR, 0.56; 95% CI, 0.42 to 0.74).
Conclusions—Available studies show convincingly the health benefits of lifestyle changes in CAD patients. Effect
estimates of combined dietary changes look promising. Future studies should confirm these findings and assess the
contribution of the individual dietary factors. (Circulation. 2005;112:924-934.)
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More than 40 years ago, Ancel Keys1 was the first toexplore the relationship between coronary artery disease
(CAD) and environmental factors. Since then, several lifestyle
and dietary factors have been found to be associated with the risk
of cardiovascular morbidity and mortality.2 This knowledge has
been translated into recommendations for the general population
(primary prevention) and clinical guidelines for those with
manifest cardiovascular diseases (secondary prevention).
Patients with CAD, ie, myocardial infarction (MI) or
angina pectoris (AP), are the largest of the secondary preven-
tion groups. This group is characterized by older age (80%
are older than 50 years) and a minority of women (30%).3
Although the prognosis of CAD patients has improved
considerably during the last decades,4 they still carry a high
absolute risk for future CAD events (10-year absolute risk
from 20% to 80%).5 International guidelines6 defined this
patient group as top priority for preventive strategies.
Guidelines for CAD prevention6–10 agree more or less on the
9 lifestyle and dietary recommendations shown in Table 1.
These recommendations are supported largely by evidence from
population-based cohort studies and trials with surrogate end
points. The effects on life expectancy in patients with CAD are
unclear. These patients differ from the general population not
only by their older age and compromised vasculature but also by
the drugs they take to prevent secondary events. Patients
contemplating behavioral changes, as well as professionals
designing preventive strategies, want to be able to make choices
and rationally prioritize one goal before another. Information on
the magnitude of the effect that can be expected of each of the
recommended lifestyle and dietary changes is therefore needed.
This study seeks to summarize the evidence that the
individual lifestyle and dietary goals formulated in Table 1
can improve prognosis in CAD patients. Second, we want to
provide estimates of the magnitude of the effects on survival
for each individual lifestyle and dietary goal based on the
available studies in CAD patients.
Methods
We conducted a systematic review of the literature on benefits of the
recommended lifestyle and dietary changes in CAD patients apply-
ing the following selection criteria.
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Study Population
Studies had to investigate a population of at least 50% patients
diagnosed with CAD. CAD patients were defined as patients with a
history of MI or AP or who underwent coronary artery bypass graft
(CABG) or percutaneous transluminal coronary angioplasty (PTCA).
Determinants and Interventions
We excluded studies on nutrient supplements if the dosage of the
nutrient they provide goes beyond the amount that can reasonably be
achieved by changing food habits without the use of supplements.
For each lifestyle and dietary recommendation (Table 1), we defined
the following determinants or interventions to be accepted in our
study.
Smoking Cessation
Studies reporting smoking cessation after the diagnosis of CAD were
accepted.
Physical Activity
Time spent on moderate intensive activity is the best example of
operationalization of the current recommendations.11 Moderately
intensive activities are those with an absolute intensity of 4 to 6
METs or a relative intensity of 40% to 60% of V˙ O2max.12 We also
accepted studies on total energy expenditure, habitual daily activity
scores, time spent in vigorous intensive physical activity, physical
fitness, or participation in structured exercise programs.
Alcohol Consumption
Alcohol consumption had to be reported in the number of units or
grams of alcohol per day. Studies reporting only alcohol intake as a
percentage of total energy intake were excluded.
Energy Balance
The recommendation to maintain or attain a healthy body weight
refers to both the actual as well as the previous history of the balance
between energy intake and energy expenditure (physical activity).
Accepted were studies on body weight maintenance after the first
manifestation of CAD and studies on intentional body weight
reduction in overweight or obese CAD patients in relation to
survival. Studies on the association between body weight status
(body mass index [BMI]) at time of event and survival were
excluded because BMI at time of diagnosis does not reflect lifestyle
and dietary habits after the first manifestation of CAD.
Saturated Fat and Trans–Fatty Acids
We accepted all studies investigating a reduced intake of saturated
fat and/or trans–fatty acids without a substantial restriction of total
fat intake. Interventions on total fat intake restrictions beyond 25
energy% were excluded because of supposed detrimental effects on
HDL and triglyceride levels.13 Given the mean intake of saturated fat
in most Western countries at 15 energy%, we defined a reduction
of 5 energy% as a relevant difference.
Regular Fish (Oil) Consumption
The recommended 2 portions (400 g) of oily fish per week are
equivalent to a daily dose of 500 to 1000 mg -3 fatty acids
(eicosapentaenoic acid [EPA] and docosahexaenoic acid [DHA]).14
We accepted all studies on fish consumption and on fish oil
supplements to a maximum increase of 1000 mg -3 fatty acids per
day. We excluded studies with higher doses because it is unlikely
that these levels can be achieved by increasing fish consumption
alone.
Fruits and Vegetables
We included studies that examined the effect of the daily intake of
fruits and vegetables in all available forms (fresh, canned, frozen,
dried, or as juice).
Whole Grains, Legumes, and Nuts
We included studies on the effect of the daily intake of whole grains,
legumes, and nuts or that studied the effect of intake of fiber from
these products.
Salt
We included all studies examining the effect of sodium restriction.
Because the recommended maximal salt intake is 6 g/d15 (2400 mg
or 100 mmol sodium) and current intake in Western societies is 9
g, a restriction was defined as a reduction of at least 30% or 50 mmol
sodium.
Combined Lifestyle and Dietary Interventions or
Combined Determinant Scores
We also included studies that examined a combination of 2 of the
aforementioned individual factors.
Outcome Measures
We only included studies that reported an effect on all-causes
mortality.
Study Design and Follow-Up Period
Studies had to have a prospective design, being either a cohort study
or a randomized controlled trial, and the follow-up period had to be
at least 6 months. If available, meta-analyses of prospective studies
were preferred and replaced the individual studies that they
described.
Search Strategy
Data for this review were identified by searches in PubMed (1966 to
May 2004) with the Medical Subject Heading (MeSH) terms
coronary artery disease and patients in combination with the MeSH
terms or text words lifestyle, smoking, physical activity, physical
fitness, exercise, alcohol drinking, body weight, weight control, diet,
saturated fat, trans–fatty acids, cholesterol, fish, fruit, vegetables,
whole grains, cereals, legumes, nuts, fiber, salt, sodium, mortality,
survival, and death. There was a restriction on English language.
Relevant articles not identified by this strategy, but referenced in the
bibliographies of these selected articles, were also included.
Data Extraction and Standardization
Details of the included studies were systematically described as
shown in Table 2. The relative risk (RR) was used as a measure of
TABLE 1. Recommendations on Lifestyle and Dietary Factors to Improve Prognosis in CAD Patients
1. Stop smoking
2. Engage in moderate intensive physical activity (for 30 minutes on at least 5, but preferably all, days of the week)
3. If you use alcohol: do so in moderation (maximum 2 alcoholic drinks per day for women and maximum 3 drinks per day for men)
4. Maintain or attain a healthy body weight (BMI 25 kg/m2); obese patients (BMI 30 kg/m2) should try to lose 10–15% of their current body weight
5. Limit your saturated fat intake (to a maximum of 10 energy%) and the intake of trans fatty acids (to maximal 1 energy%)
6. Consume fish regularly (at least 1 and preferably 2 portions of oily fish per week)
7. Consume sufficient amounts of fruits and vegetables (400 g/d)
8. Use sufficient fiber containing grain products, legumes, and/or nuts (3 U/d)
9. Reduce your salt intake (to maximal 2400 mg/d)
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strength of the relationship between exposure to the lifestyle or
dietary factor and all-causes mortality or other end points. The RR
should compare the risk in the group practicing the desired healthy
behavior (exposed group) with the group not showing the healthy
behavior (reference group). For studies that reported the RR from the
unhealthy lifestyle or dietary factor (eg, BMI 30 kg/m2) compared
with the healthy lifestyle or dietary factor (eg, BMI 25 kg/m2), the
RR from the exposed group was calculated as 1 divided by the RR
in the nonexposed group. If the RR or the 95% CI of the RR was not
reported in the original studies, they were calculated from the study
data with the use of the number of subjects (N) and the number of
cases (A) in both the exposed (1) and the unexposed (0) groups:
RR(A1/N1 divided by A0/N0) and 95% CIEXP[lnRR1.96(1/
A11/A0)] if incidence is sufficiently rare.
Summary Effect Estimates
We decided that an effect estimate per lifestyle or dietary goal could
only be provided if a meta-analysis was available or if at least 2
randomized controlled trials or 2 cohort studies were available
meeting the following quality criteria: in case of cohort studies, the
effect estimate should be based on findings that were adjusted for
confounders, at least for age and gender; in case of randomized trials,
information should be given that compliance with the intervention
under study was checked and considered satisfactory; and the effect
estimate of each study should be based on at least 20 mortality cases
to guarantee that the power of the study allowed meaningful effect
estimation.
Results for the lifestyle or dietary goals that fulfilled these criteria
are shown in Table 3. Before we pooled the data, heterogeneity
between the studies was tested with the 2 statistic. We used the
random effects model for calculating a pooled estimate for the RR if
the probability value for heterogeneity was 0.5. In case the
probability value for heterogeneity was 0.5, a fixed effects model
was used.
Results
A total of 3 meta-analyses, 10 randomized controlled trials
(studying 13 interventions), and 9 cohort studies fulfilled the
inclusion criteria. Details of the available studies per lifestyle
or dietary goal are shown in Table 2. For 5 goals (3 on
lifestyle and 2 on dietary changes), the available studies
fulfilled our additional criteria for calculating pooled effect
size estimates (Table 3). For the combined interventions, only
studies on combined dietary changes were available, and their
pooled effect estimate is shown in Table 3.
Goals With Sufficient Studies to Calculate a
Pooled Effect Estimate
Smoking Cessation
Two meta-analyses of cohort studies were found on smoking
cessation. Duration of follow-up ranged from 2 to 20 years.
All included studies consistently showed a protective effect
of smoking cessation. Wilson et al16 performed a meta-
analyses of 12 studies in patients with MI and found a pooled
RR for all-causes mortality of 0.54 (95% CI, 0.46 to 0.62) for
those who had quit smoking. Critchley and Capewell17
published a meta-analysis of 20 studies in patients with
previous MI or AP and reported a pooled RR of 0.64 (95%
CI, 0.58 to 0.71). Half of the studies were the same as in the
first analysis. On the basis of these 2 meta-analyses, we
conservatively estimate the effect size of smoking cessation
in CAD patients as a 35% mortality risk reduction.
Habitual Physical Activity
We found no studies on the effect of increased physical
activity on mortality in CAD patients. The effect of partici-
pation in a structured exercise program after a cardiac event
(MI, AP, CABG, or PTCA) on morbidity and mortality has
been evaluated in several meta-analyses.18–22 Reported effect
size estimates of mortality reduction varied between 20% and
25%. Here we review the analysis by Brown et al,21 which is
a 2003 update from earlier meta-analyses and which studied
exercise-based rehabilitation programs separately from the
comprehensive rehabilitation programs that also included
educational and psychosocial interventions. In this study
mortality data were available of 2585 patients in 12 random-
ized controlled trials. The interventions varied widely from
gym-based aerobic exercise twice a week for 4 weeks to
interventions lasting for 30 months with inpatient stays. Mean
follow-up time was 24 months (range, 6 to 60 months). The
study showed a significant beneficial effect of an exercise
program. The effect on all-causes mortality was estimated as
25% risk reduction (RR, 0.76; 95% CI, 0.59 to 0.98).
Moderate Alcohol Consumption
We found 5 cohort studies23–27 examining the effect of
moderate drinking versus rare drinkers or nondrinkers in
CAD patients. All studies, except for 1,24 found a statistically
significant reduction of all-causes mortality between 15% and
25% for moderate drinking. Duration of follow-up varied
between 3 and 13 years. Effect estimates are shown in Table
3. The pooled effect estimate for the RR for all-causes
mortality in the 5 studies was 0.80 (P for heterogeneity 0.53;
95% CI, 0.78 to 0.83), summarized in an effect estimate of
20% reduction of all-causes mortality.
Saturated Fat Reduction
Four28–31 randomized controlled trials and 1 cohort study32
met our criteria for fat modification. They all concerned
saturated fat intake reduction. No studies were detected on the
relation between trans–fatty acid intake and mortality in CAD
patients. The randomized controlled trials were performed
between 1960 and 1988 and intended to study a reduction of
5 energy% in saturated fat intake during 2 to 5 years of
follow-up. The resulting reduction in serum cholesterol was
15% in 2 studies28,29 and only 5% in the other 2,31 raising
doubts on adherence to the regimen in the latter 2 studies.30
Only in the 2 studies with the largest serum cholesterol
reductions was total mortality reduced (12% and 25%), but
the power of the studies was too limited to show statistically
significant reductions. The probability value for heterogene-
ity was 0.18 for the 4 studies and 0.63 when the 2 studies with
unsatisfying serum cholesterol reductions were excluded. The
pooled effect estimates were not statistically significant for
either the 4 or the 2 studies (Table 3). The cohort study32 in
400 Finnish CAD patients was supportive of a beneficial
effect of a lower saturated fat intake. For every 4 energy%
reduction in saturated fat, intake RR for all-causes mortality
was 0.64 (95% CI, 0.46 to 0.88). However, this study on its
own is not sufficient to be conclusive. Because the pooled
effects are not statistically significant, we provide no sum-
mary effect estimate for saturated fat restriction.
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TABLE 2. Studies on Lifestyle and Dietary Factors and All-Causes Mortality in CAD Patients
Study Study Population Enrollment/Follow-up Determinant/Intervention Reference/Controls
All-Causes Mortality,
RR (95% CI)
Smoking cessation
Critchley, 2003
Meta-analysis
20 cohort studies
CAD patients n12 603;
2928 deaths
Age: 20–95 y
70% men
Enrollment: 1960–1995
Mean follow-up: 5.5 y
Smoking cessation after CAD
diagnosis
Continued smoking 0.64 (0.58–0.71)
Wilson, 2000
Meta-analysis
12 cohort studies
Post-MI patients
n5878; 915 deaths
Age: not reported
Enrollment: 1949–1988
Follow-up: 2–10 y
Smoking cessation after MI
diagnosis
Continued smoking 0.54 (0.46–0.62)
Physical activity
Brown, 2003
Meta-analysis
12 RCTs
CAD patients
n2585; 212 deaths
Age: 54 (50–70) y
95% men
Enrollment: 1970–2000
Mean follow-up: 2 y
(range, 6 mo–5 y)
Rehabilitation program with
exercise only
Usual care 0.76 (0.59–0.98)
Moderate alcohol
consumption
Cooper, 2000
Cohort study
US
CAD patients with left
ventricular dysfunction
n5331; 1200 deaths
Mean age: 60 y
85% men
Enrollment: 1990
Follow-up: 33 14 mo
Adjustments: demographics,
risk factors, medication
1–4 alcoholic drinks per week No alcohol drinkers 0.85 (0.75–0.97)
Shaper, 2000
Cohort study
UK
CAD patients
n655; 294 deaths
Age: 40–59 y at baseline
100% men
Enrollment: 1983–1985
Follow-up: 12.8 y
Adjustments: demographics,
risk factors
1–15 U/wk Occasional drinking 1.05 (0.78–1.42)
Muntwyler, 1998
Cohort study
US
Post-MI patients
n5358; 920 deaths
Mean age: 63 (9) y
100% men
Enrollment: 1982
Follow-up: 5 y
Adjustments: demographics,
risk factors
2–6 U/wk Rare and non-drinkers 0.72 (0.58–0.89)
Thun, 1997
Cohort study
US
Patients with vascular disease
n71 232; 8434 deaths
Mean age: 57 y
55% men
Enrollment: 1982
Follow-up: 9 y
Adjustments: demographics,
risk factors, fat intake
2 drinks per day Non-drinkers (ex-drinkers
excluded)
0.8 (0.8–0.9)
Doll, 1994
Cohort study
UK
Patients with vascular disease
n5402; 2396 deaths
Age: 48–78 y
100% men
Enrollment: 1978
Follow-up: 13 y
Adjustments: age, smoking
1–14 U/wk Non-drinkers
(including ex-drinkers)
0.79* (0.69–0.91)
Body weight control
Singh, 1992
Cohort study
India
CAD patients
n204; 21 deaths
Age: 51 9 y
90% men
Enrollment: not reported
Follow-up: 1 y
Adjustments: none
Weight loss after MI 0.5 kg Weight loss after MI 0.5 kg 0.46* (0.19–1.10)
Saturated fat
Erkkila, 2003
Cohort study
Finland
CAD patients
n415; 34 deaths
Age: 61 (33–74) y
70% men
Enrollment: 1991–1994
Follow-up: 5 y
Adjustments: demographic
and diagnostic factors, risk
factors, energy intake
9 energy% saturated fat
(average, SD)
13 energy% saturated fat
(average)
0.64 (0.46–0.88)
Burr, 1989
RCT
UK
Post-MI patients
n2033; 224 deaths
Mean age: 57 y
100% men
Enrollment: 1985–1987
Follow-up: 2 y
Compliance: moderate; as
shown by 5% decrease in
serum cholesterol
11 energy% saturated fat 15 energy% saturated fat 1.0 (0.77- 1.30)
Woodhill, 1978
RCT
Australia
CAD patients
n458; 67 deaths
Age: 30–59 y
100% men
Enrollment: 1966–1972
Follow-up: 5 y
Compliance: moderate, as
shown by 5% decrease in
serum cholesterol
10 energy% saturated fat 13.5 energy% saturated fat 1.49* (0.92–2.43)
Morris, 1968
RCT
UK
Post-MI patients
n395; 59 deaths
Age: 60% 50–60 y
100% men
Enrollment: 1960–1965
Mean follow-up: 3.7 y
Compliance: good, as shown
by a 15% decrease in serum
cholesterol
12 energy% saturated fat 17 energy% saturated fat
(ordinary UK diet)
0.88*
(0.53–1.47)
Leren, 1966
RCT
Norway
Post-MI patients
n412; 96 deaths
Age: 30–64 y
100% men
Enrollment: 1958–1959
Follow-up: 5 y
Compliance: good, shown by
a 15% decrease in serum
cholesterol
9 energy% saturated fat Not described 0.75*
(0.50–1.12)
Regular fish (oil) consumption
Barzi, 2003
Cohort study
Italy
Post-MI patients
n11 246; 1660 deaths
Age: 59 11 y
85% men
Enrollment: 1993–1995
Follow-up: 6.5 y
Adjustments: demographic,
risk factors, food variables
2 portions of fish per week (Almost) never fish 0.81 (0.69–0.94)
Erkkila, 2003
Cohort study
Finland
CAD patients
n400; 34 deaths
Age 61 (33–74) y
70% men
Enrollment: 1991–1994
Follow-up: 5 y
Adjustments: demographic,
diagnostic, risk factors, energy
intake
1–57 g fish per day
57 g fish per day
0 g fish per day
0 g fish per day
0.50 (0.20–1.28)
0.37 (0.14–1.00)
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Regular Fish (Oil) Consumption
We found 3 randomized controlled trials31,33–35 and 2 cohort
studies32,36 fulfilling our selection criteria. The trials tested
either the effect of advice to increase fatty fish consumption
up to 200 to 400 g/wk31,33 or the effect of a fish oil
supplement containing 900 mg EPA and DHA per day.34,35
Two of them31,34,35 showed a significant mortality reduction,
but the trial in AP patients33 found a nonsignificant mortality
increase in the intervention group.
Both cohort studies were supportive of a protective effect
of a higher fish intake. The study by Barzi et al36 (n11 246)
was performed in the participants of the GISSI-Prevenzione
trial studying the effects of fish oil (900 mg EPA and DHA)
and/or vitamin E (300 mg) supplements. Irrespective of their
assignment to the study intervention, most patients increased
their fish consumption subsequent to the MI, as was advised
by the hospital. Fish intake was assessed 4 times during the
intervention period of 3.5 years, and duration of follow-up
TABLE 2. Continued
Study Study Population Enrollment/Follow-up Determinant/Intervention Reference/Controls
All-Causes Mortality,
RR (95% CI)
Burr, 2003
RCT
UK
AP patients
n3114; 525 deaths
Mean age: 61 y
100% men
Enrollment: 1990–1996
Follow-up: 3 to 9 y
Compliance checked by food
records in subset at 6 mo; no
significant difference in serum
EPA level between groups
Advice to eat at least 2
weekly portions of oily fish
(200–400 g) or fish oil
capsules
“Sensible eating” advice 1.15 (0.96–1.36)
GISSI, 1999/2002
RCT
Italy
Post-MI patients
n11 323; 1017 deaths
Mean age: 59 11 y
85% men
Enrollment: 1993–1995
Follow-up: 3.5 y
Compliance confirmed 3-mo
by biomarkers and refill check
drug supplies
Supplement 900 mg EPA/DHA Placebo 0.79 (0.66–0.93)
Burr, 1989
RCT
UK
Post-MI patients
n2033; 224 deaths
Mean age: 57 y
100% men
Enrollment: 1985–1987
Follow-up: 2 y
Compliance confirmed at 6
mo and at 2 y by food
records and biomarkers
(serum EPA)
Advice: eat at least 2 weekly
portions of oily fish (200–400
g) or fish oil capsules
“Sensible eating” advice 0.71 (0.54–0.93)
Fruit and vegetables
Burr, 2003
RCT
UK
AP patients
n3114; 525 deaths
Mean age: 61 y
100% men
Enrollment: 1990–1996
Follow-up: 3–9 y
Compliance: bad; no change
in biomarkers (serum levels of
folate and carotenoids)
Advice: 4–5 portions of fruit
and vegetables plus 1 glass
of orange juice
“Sensible eating” advice 1.12 (0.94–1.34)
Barzi, 2003
Cohort study
Italy
Post-MI patients
n11 246; 1660 deaths
Age: 59 11 y
85% men
Enrollment: 1993–1995
Follow-up: 6.5 y
Intake measured 4 times in
3.5 y
Adjustments: demographic.
Risk factors, food variables
Fruit: 1 time per day
Raw vegetables: 1 time per
day
Cooked vegetables: 1 time
per day
(Almost) never fruit
(Almost) never raw vegetables
(Almost) never cooked
vegetables
Fruit: 0.73 (0.54–0.98)
Raw: 0.67 (0.56–0.79)
Cooked: 0.84 (0.71–1.00)
Whole grains, legumes,
and nuts
Erkkila, 2003
Cohort study
Finland
CAD patients
n400; 34 deaths
Mean age: 61 y
70% men
Enrollment: 1991–1994
Follow-up: 5 y
Adjustments: demographic
and diagnostic factors, risk
factors, energy intake
30 g fiber/d 22 g fiber/d 0.81 (0.55–1.19)
Burr, 1989
RCT
UK
Post-MI patients
n2033; 224 deaths
Mean age: 57 y
100% men
Enrollment: 1985–1987
Follow-up: 2 y
Compliance confirmed by
food records at 6 mo and 2
y, no biomarkers
30 g total fiber, of which 20 g
cereal fiber
20 g total fiber, of which 10 g
cereal fiber
1.27 (0.99–1.65)
Combined lifestyle factor
studies
Barzi, 2003
Cohort study
Italy
Post-MI patients
n11 246; 1660 deaths
age: 59 11 y
85% men
Enrollment: 1993–1995
Follow-up: 6.5 y
Adjustments: demographic,
risk factors, food variables
4th quartile of dietary score
for intake of fish, fruit,
vegetables, olive oil
Lowest quartile of dietary
score
0.51 (0.44–0.59)
Singh, 2002
RCT
India
High-risk patients
(59% CAD)
n1000, 65 deaths
Age: 49 10 y
90% men
Enrollment: not reported
Follow-up: 2 y
Compliance was confirmed by
3-mo food records
Advice: AHA step 1 diet plus
extra fruits, vegetables, whole
grains, legumes, nuts, and
-linolenic acid–rich oil
Advice: AHA step 1 diet: 30
energy% fat, 10 energy%
saturated fat, 300 mg
cholesterol/d
0.63* (0.38–1.06)
De Lorgeril, 1994/1999
RCT
France
Post first MI-patients
n605; 38 deaths
Mean age: 53.5 y
90% men
Enrollment: 1988–1992
Follow-up: 3.8 y
Compliance was checked at
each visit by 24-h recall and
food frequency questionnaire
and confirmed by biomarkers
(plasma fatty acids)
Advice: Mediterranean diet
and supply with -linolenic
acid–enriched margarine
Advice: AHA step 1 diet: 30
energy% fat, 10 energy%
saturated fat, 300 mg
cholesterol/d
0.44 (0.21- 0.94)
Singh, 1992
RCT
India
Post-MI patients
n406; 59 deaths
Mean age: 51 10 y
90% men
Enrollment: 24 h after MI
Follow-up: 1 y
Compliance was confirmed by
3-mo food records
AHA step 1 diet plus extra
fruits and vegetables (400
g/d), legumes, nuts, and fish
Advice: AHA step 1 diet: 30
energy% fat, 10 energy%
saturated fat, 300 mg
cholesterol/d
0.55 (0.34–0.75)
RCT indicates randomized controlled trial; AHA, American Heart Association.
*RR not reported but calculated from study data (see Methods).
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was 6.5 years. In the small cohort study by Erkkila et al,32 fish
consumption was assessed at baseline only, and patients were
followed up for 5 years. Both cohort studies fulfilled our
quality criteria on adjustment for confounding and the num-
ber of cases. Table 3 shows the effect estimates of the
presented studies. Before the data were pooled, heterogeneity
tests were performed. Heterogeneity existed (P0.002) for
the 3 fish trials but disappeared when the AP patients’ trial
was excluded (P0.56). Pooled effect estimates for both the
3 and the 2 trials as well as for the 2 cohort studies are shown
in Table 3. Because of the unexplained heterogeneity in the
results, no summary effect estimate is provided for regular
fish (oil) consumption.
Remaining Goals
For the remaining dietary goals, the available studies (Table
2) were insufficient to provide a reliable effect estimate on
life expectancy in CAD patients. For body weight control, we
found only 1 study37 on the effect of weight reduction after
MI, but this study was considered of low quality because the
results were not adjusted for confounding, not even for age
and gender. For fruits and vegetables, the available random-
ized controlled trial33 was not a good test for the effect of
increased fruit and vegetable consumption because compli-
ance with the intervention was doubted as a result of a lack of
any rise in serum concentrations of folate or carotenoids. The
cohort study by Barzi et al36 supported a beneficial effect of
the recommendations on both fruit (RR, 0.73; 95% CI, 0.54 to
0.98) and vegetables (raw vegetables: RR, 0.67; 95% CI, 0.56
to 0.79; cooked vegetables: RR, 0.84; 95% CI, 0.71 to 1.00)
but was insufficient on its own to be included in Table 3. For
dietary fiber and whole grain products, available studies were
not consistent. The only trial31 showed no effect (because
compliance was not measured, it is unclear whether this is
TABLE 3. Mortality Reduction Estimates of Lifestyle and Dietary Changes Based on Available
Studies in CAD Patients
Goals
Randomized Controlled Trials,
RR (95% CI)
Prospective Cohort Studies,
RR (95% CI)
Lifestyle factors
Smoking cessation Critchley,* 2003, 0.64 (0.58–0.71)
Wilson,* 2000, 0.54 (0.46–0.62)
Physical activity Brown,* 2003, 0.76 (0.59–0.98)
Moderate alcohol consumption Cooper, 2000, 0.85 (0.75–0.97)
Shaper, 2000, 1.05 (0.78–1.42)
Muntwyler, 1998, 0.72 (0.58–0.89)
Thun, 1997, 0.8 (0.8–0.9)
Doll, 1994, 0.79 (0.69–0.91)
Pooled estimate: 0.80 (0.78–0.83)†
Dietary factors
Saturated fat reduction Burr, 1989, 1.0 (0.77–1.30) Erkkila, 2003, 0.64 (0.46–0.88)
Woodhill, 1978, 1.49 (0.92–2.43)
Morris, 1968, 0.88 (0.53–1.47)
Leren, 1966, 0.75 (0.50–1.12)
Pooled (4 studies): 0.98 (0.81–1.18)§
Pooled (2 studies)‡: 0.79 (0.58–1.09)†
Regular fish (oil) consumption Burr, 2003, 1.15 (0.96–1.36) Barzi, 2003, 0.81 (0.69–0.94)
GISSI, 1999, 0.79 (0.66–0.93) Erkkila, 2003, 0.50 (0.20–1.28)
Burr, 1989, 0.71 (0.54–0.93)
Pooled (3 studies): 0.88 (0.69–1.11)§ Pooled estimate: 0.80 (0.69–0.93)†
Pooled (2 studies): 0.77 (0.66–0.89)†
Combined factors
Combined dietary factors Singh, 2002, 0.63 (0.38–1.06) Barzi, 2003, 0.51 (0.44–0.59)
Lorgeril, 1999, 0.44 (0.21–0.94)
Singh, 1992, 0.55 (0.34–0.75)
Pooled estimate: 0.55 (0.41–0.74)†
*Meta-analysis.
†P for heterogeneity 0.5; fixed effects model used.
‡Studies by Burr, 1989 and Woodhill, 1978 excluded.
§P for heterogeneity 0.5; random effects model used.
Study by Burr et al, 2003 excluded.
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due to a lack of effect or a lack of compliance), and the cohort
study32 on total fiber intake was too small (n400; 34
mortality cases) to show a statistically significant difference
(RR, 0.81; 95% CI, 0.55 to 1.19). No studies were found
relating the intake of trans–fatty acids, legumes, nuts, or salt
to mortality in CAD patients.
Combined Interventions
We found no studies on the mortality effects of combinations
of both lifestyle and dietary changes. On combined dietary
changes alone, 3 randomized controlled trials37–40 and 1
cohort study36 met our inclusion criteria for the summary
effect estimate. The interventions consisted of an increased
intake of fiber-rich foods (fruits, vegetables, nuts, legumes)
and fish and eventually an enhanced intake of unsaturated
fatty acid intake through the use of oils or special margarines.
Average duration of follow-up varied between 1 and 4 years.
Mortality reduction was statistically significant in 2 of the 3
trials.37,39 Both the individual and the pooled effect estimates
on mortality are shown in Table 3. The pooled RR for
all-causes mortality was 0.56 (P for heterogeneity0.73;
95% CI, 0.42 to 0.74). The effect estimate in the cohort
study36 was based on a combined score on the consumption of
fish, fruit, cooked vegetables, raw vegetables, and olive oil.
All-causes mortality was 49% lower in patients in the highest
quartile of the dietary score compared with the lowest
quartile. We estimate the mortality risk reduction potential for
combinations of individual dietary goals (as formulated in
Table 1) to be 45%.
Discussion
Although many of the commonly provided lifestyle and
dietary recommendations (Table 1) are supported with evi-
dence from surrogate end point studies and studies in the
general population, there is only limited evidence from
studies in CAD patients that these recommendations indeed
improve their life expectancy. The available studies show
significant effects for 3 lifestyle recommendations on prog-
nosis of CAD patients. Effects for smoking cessation, in-
creased physical activity, and moderate alcohol consumption
vary from a 20% to 35% reduction in all-causes mortality. For
individual dietary goals, evidence from studies in CAD
patients was not available or was too limited to provide
reliable effect estimates. A few studies on combinations of
dietary changes show promising results, with mortality re-
ductions of 45%.
In this review we included both experimental and obser-
vational studies. Randomized controlled trials are generally
rated as a higher level of evidence than prospective cohort
studies because they exclude self-selection and confounding
by indication as a source of bias. Randomized clinical trials,
however, have their own drawbacks: their inclusion criteria
often limit generalization to the average patient population in
routine care, their costs often limit the duration of the study,
in the case of lifestyle or dietary interventions double blind-
ing is often impossible, or the intervention itself is unethical
(eg, smoking or alcohol consumption). Prospective cohort
studies, on the other hand, may be confounded by unknown
prognostic factors associated with lifestyle or dietary habits,
but they have the advantage of giving a better reflection of the
“real-life” situation with long-term exposure and mostly a
mixed patient population. The advantages and disadvantages
of each design do not outweigh those of the other. In this
review we reported effect sizes of both study designs (if
available) separately and did not make an attempt to rank one
above the other.
This review has several potential limitations. Most evi-
dence was available for studies on lifestyle changes in CAD
patients. Studies on dietary changes are scarce, and several
are of poor methodological quality. Confounding due to
clustering of lifestyle and dietary factors as well as bias
because of unblinding or poor compliance with the interven-
tion or changes in habits of the control group is more common
in lifestyle and dietary studies than in drugs trials. Many of
the studies included in this review were underpowered to
assess effects on total mortality. This problem may be solved
by pooling the results of individual studies, but, even if tests
for heterogeneity are not significant, this operation may be
problematic because of the heterogeneity of studies with
respect to background habits, intervention characteristics,
exposure (time and dose), and length of follow-up. Some-
times the point estimates are impressive, but the wide CIs
indicate a high degree of uncertainty. Therefore, caution is
needed in interpreting the results and particularly in translat-
ing the effect size estimates to the individual patient.
Nevertheless, most of the presented effect estimates are in
accord with results from studies performed in the general
population. Table 4 compares the effect estimates in CAD
patients with results from cohort studies in the general
population.
Smoking Cessation
Our effect estimate of 35% risk reduction is similar to
findings from population-based cohort studies indicating that
quitters before age 50 have a 50% lower risk of dying than
continuing smokers.41,42
TABLE 4. Approximate Mortality Reduction Potential of Lifestyle and Dietary
Changes Estimated From Studies in CAD Patients and the General Population
Recommendation
Mortality Risk Reduction
Estimated From Studies
in CAD Patients
Mortality Risk Reduction
Estimated From Cohort Studies
in General Population
Smoking cessation 35% 50%
Physical activity 25% 20%–30%
Moderate alcohol 20% 15%
Combined dietary changes 45% 15%–40%
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Physical Activity Level
An effect estimate of 25% mortality risk reduction for an
increased level of physical activity was obtained from a
meta-analysis on the effect of exercise-based revalidation.
Although the best available, this is not a good estimate for
adherence to the guideline11 to increase habitual physical
activity level to a daily amount of at least 30 minutes of
moderately intensive activity. Participation in a program is
not necessarily related to a higher physical activity level in
the long run.43,44 However, the estimated 25% mortality risk
reduction compares well with estimates from other popula-
tions. A review45 of 44 population-based cohort studies
reported that adherence to the guideline was associated with
a 20% to 30% reduction in all-causes mortality. Further
reductions were observed at higher volumes of energy expen-
diture. Not only high baseline levels but also increments in
physical activity level later in life are shown to be associated
with lower mortality.46,47
Alcohol
Although the protective effect of moderate alcohol consump-
tion on cardiovascular risk has been sufficiently demonstrated
in the general population cohorts,48 for CAD patients there
was concern about the adverse effects on the cardiovascular
system, such as hypertension, arrhythmias, hemorrhagic
stroke, and cardiomyopathy.49 The presented studies are
consistent in their finding that moderate alcohol consumption
can improve the prognosis in CAD patients, even in patients
with associated heart failure,23 as long as the alcohol intake is
moderate (2 to 3 U/d). The estimate of 20% mortality risk
reduction in CAD patients is in range with a pooled estimate
of 15% mortality reduction in cohort studies in middle-aged
populations.50 Of course, the benefits of moderate alcohol
consumption should always be mentioned in relation to the
potential risks of excessive alcohol consumption because
there are still more deaths caused by alcohol than prevented.51
Saturated Fat
Reliable effect estimates could be provided for none of the
individual dietary factors. The pooled effect estimates for
saturated fat reduction were not statistically significant (for
the 4 studies: RR, 0.98; 95% CI, 0.81 to 1.18) but agreed with
the findings of 2 meta-analyses on fat modification combin-
ing the results of both primary and secondary prevention
trials: RR, 0.94 (95% CI, 0.89 to 0.99; 17 trials)52 and RR,
0.98 (95% CI, 0.86 to 1.12; 11 trials).53 In contrast to our
study, these meta-analyses also included studies on total fat
restriction, which might have attenuated the effect. They
confirm our finding that a trend was seen toward a greater risk
reduction in trials in which better adherence to the interven-
tion is shown by a greater reduction in serum cholesterol.
Regular Fish (Oil) Consumption
There was heterogeneity between the studies, but the calcu-
lated pooled effect estimates for the trials (12% to 23%
mortality risk reduction) are in agreement with an estimate of
20% all-causes mortality reduction in a meta-analysis by
Bucher et al54 based on 9 trials in CAD patients on the effects
of dietary fish or fish oil supplementation in doses up to 10 g
of -3 fatty acids per day. The pooled effect estimate from
the cohort studies in CAD patients was also 20%. Data on fish
and all-causes mortality from population-based cohorts are
inconsistent and vary from 0% to 30%.55–60 Null findings in
some of the studies can possibly be explained by the adverse
effects of the high mercury content of fish in some geographic
areas56,61 or by the fact that the protective effect is specific for
fatty fish and not for total fish consumption.62 The association
with CAD mortality is more frequently studied than all-
causes mortality, and significant risk reductions are
reported.63–65
For the remaining individual goals, studies on mortality
were too few to provide effect estimates. This should not be
interpreted as a lack of scientific support for these recom-
mendations. The evidence from surrogate end point or clini-
cal end point studies is reviewed elsewhere.66–77 Studies on
all-causes mortality, however, are scarce, not only in CAD
patients but also in other populations. Given the alarming
signals78,79 on a high prevalence (80%) of overweight and
obesity in CAD patients, it is surprising that no studies were
found on the effect of intentional weight loss on mortality in
CAD patients. Weight loss might be one of the mechanisms
through which other lifestyle or dietary changes (eg, regular
exercise or increased intake of whole grains and vegetables)
might exert their protective effect, but few authors report on
body weight changes.40 Cohort studies in the general popu-
lation have shown that mortality is 30% to 50% lower in
normal-weight individuals than in their obese peers,80 al-
though this difference decreases with age.81 The effect that
can be expected from weight reduction in patients already
treated with preventive drugs is unclear. Some studies in
CAD patients82–86 (not meeting our inclusion criteria) even
suggest a prognostic benefit of obesity. These studies, how-
ever, are inconclusive because they often lack appropriate
adjustments for confounding (eg, confounding by age be-
cause obese persons are generally 7 years younger at time of
their first MI than normal-weight individuals), but they stress
the need for high-quality additional research. Finally,
population-based cohort studies that study all-causes mortal-
ity in relation to the intake of fruits and vegetables,87–90 whole
grains,87,91,92 legumes,93 nuts,94,95 or salt96–98 are scarce but
are generally supportive of a protective effect of the
recommendations.
The trials on combined dietary interventions showed im-
pressive results, varying from 35% to 55% mortality reduc-
tion. Other intervention studies in CAD patients showed
benefits of combined lifestyle and dietary changes on surro-
gate end points and cardiac events.99,100 The cohort study in
11 000 CAD patients by Barzi et al36 showed an almost 50%
lower mortality risk for those with the highest dietary quality
score. Mortality risk reductions associated with dietary qual-
ity reported from other populations were generally smaller
(15% to 25%), but a significant benefit was demonstrated in
many studies.101–110 Two studies in elderly people101,104
showed a 60% to 70% lower mortality associated with a
higher quality score for a combination of both lifestyle and
dietary habits. Although the studies on combined changes are
promising, they shed no light on the dominant mechanism
and on the contribution of the individual lifestyle and dietary
factors. More knowledge on the benefits of the 6 individual
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dietary goals in particular is necessary for designing effective
preventive strategies.
If the effect sizes of lifestyle and dietary changes in Table
4 reflect the true value, they compare favorably with effect
size estimates for cardiopreventive drugs as shown in Table
5.111-114 In contrast to these pharmacological interventions,
the prognostic effects of lifestyle and dietary changes are,
however, less rigorously studied. For the future, well-
designed and powered studies are needed to test the effect of
dietary changes on prognosis. Second, because compliance
with the recommendations is crucial, research is needed on
strategies to enhance adaptation and maintenance of healthy
lifestyle and dietary habits in CAD patients.
In conclusion, there is evidence from mortality studies in
CAD patients that smoking cessation, physical activity, mod-
erate alcohol consumption, and combined dietary changes
improve prognosis. Effect size estimates for the lifestyle
goals vary between 20% and 35% mortality reductions. Data
on the benefits of individual dietary goals are limited. For the
future, more and better-quality studies are needed to reduce
the uncertainty that surrounds these effect size estimates.
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